AR092354A1 - Derivados de carbamato/urea - Google Patents
Derivados de carbamato/ureaInfo
- Publication number
- AR092354A1 AR092354A1 ARP130102583A ARP130102583A AR092354A1 AR 092354 A1 AR092354 A1 AR 092354A1 AR P130102583 A ARP130102583 A AR P130102583A AR P130102583 A ARP130102583 A AR P130102583A AR 092354 A1 AR092354 A1 AR 092354A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- halogen
- amino
- once
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), o una sal del mismo, en donde R¹ es alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, cicloalquenilo C₅₋₆ o cicloalquil C₃₋₆-alquil C₁₋₄; en donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ o cicloalquilo C₃₋₆-alquilo C₁₋₄ puede ser sustituido una vez o más de una vez por halógeno, y en donde dicho cicloalquilo C₃₋₆ o cicloalquenilo C₅₋₆ pueden sustituirse una vez o más de una vez por halógeno, alquilo C₁₋₄ o halógenoalquilo C₁₋₄; m es 1 ó 2; n es 0, 1, 2, 3 ó 4; cada R² es independientemente halógeno, hidroxilo, amino, ciano, nitro, alquilo C₁₋₆, halógenoalquilo C₁₋₆, hidroxialquilo C₁₋₆, alcoxi C₁₋₄-alquilo C₁₋₆, amino-alquilo C₁₋₆, alquil C₁₋₄-amino-alquilo C₁₋₆, di(alquilo C₁₋₄)-amino-alquilo C₁₋₆, alcoxilo C₁₋₆, halógeno-alcoxilo C₁₋₆, alquilamino C₁₋₆, di(alquil C₁₋₆)amino, alquenilo C₂₋₆, halógenoalquenilo C₂₋₆, alquinilo C₂₋₆ o halógenoalquilo C₂₋₆; o cicloalquilo C₃₋₆, en donde un átomo de carbono puede reemplazarse por un átomo de oxígeno, en donde el cicloalquilo C₃₋₆ puede fijarse directamente al metileno o a través de un alquileno C₁₋₂, y en donde el cicloalquilo C₃₋₆ puede sustituirse una vez o más de una vez por halógeno; o dos R² en el mismo átomo de carbono forman junto con dicho átomo de carbono un cicloalquilo C₃₋₆; X¹ es oxígeno u oxígeno -N(R⁴)-; R⁴ es hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆, o cicloalquil C₃₋₆-alquilo C₁₋₂; p es 1 y q es 1; p es 0 y q es 1; o p es 0 y q es 0; r es 0, 1, 2, 3 ó 4; cada R³ es independientemente halógeno, hidroxilo, amino, ciano, nitro, alquilo C₁₋₆, C₁₋₆halogenalquilo, C₁₋₆hidroxialquilo, C₁₋₄alcoxi-alquilo C₁₋₆, amino-alquilo C₁₋₆, alquil C₁₋₄-amino-alquilo C₁₋₆, di(alquilo C₁₋₄)-amino-alquilo C₁₋₆, alcoxilo C₁₋₆, halógeno-alcoxilo C₁₋₆, alquilamino C₁₋₆, di(alquil C₁₋₆)amino, alquenilo C₂₋₆, halógenoalquenilo C₂₋₆, alquinilo C₂₋₆ o halógenoalquilo C₂₋₆; o cicloalquilo C₃₋₆, en donde un átomo de carbono puede reemplazarse por un átomo de oxígeno, en donde el cicloalquilo C₃₋₆ puede fijarse directamente al metileno o a través de un alquileno C₁₋₂, y en donde el cicloalquilo C₃₋₆ puede sustituirse una vez o más de una vez por halógeno; o dos R³ en el mismo átomo de carbono forman junto con dicho átomo de carbono un cicloalquilo C₃₋₆; A es un resto de fórmula (2) en donde el enlace marcado con el asterisco se fija al átomo de nitrógeno; R⁵ es hidrógeno, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, cicloalquenilo C₅₋₆ o cicloalquil C₃₋₆-alquil C₁₋₄; en donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ o cicloalquilo C₃₋₆-alquilo C₁₋₄ puede ser sustituido una vez o más de una vez por halógeno, hidroxilo o alcoxilo C₁₋₆; y en donde dicho cicloalquilo C₃₋₆ o cicloalquenilo C₅₋₆ pueden sustituirse una vez o más de una vez por halógeno, alquilo C₁₋₄ o halógenoalquilo C₁₋₄; X² es nitrógeno o carbono; s es 0, 1, 2 ó 3; cada R⁶ es independientemente halógeno, hidroxilo, amino, ciano, nitro, alquilo C₁₋₆, C₁₋₆halogenalquilo, C₁₋₆hidroxialquilo, C₁₋₄alcoxi-alquilo C₁₋₆, amino-alquilo C₁₋₆, alquil C₁₋₄-amino-alquilo C₁₋₆, di(alquilo C₁₋₄)-amino-alquilo C₁₋₆, alcoxilo C₁₋₆, halógeno-alcoxilo C₁₋₆, alquilamino C₁₋₆, di(alquil C₁₋₆)amino, alquenilo C₂₋₆, halógenoalquenilo C₂₋₆, alquinilo C₂₋₆ o halógenoalquilo C₂₋₆; o cicloalquilo C₃₋₆, en donde un átomo de carbono puede reemplazarse por un átomo de oxígeno, en donde el cicloalquilo C₃₋₆ puede fijarse directamente al metileno o a través de un alquileno C₁₋₂, y en donde el cicloalquilo C₃₋₆ puede sustituirse una vez o más de una vez por halógeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012078933 | 2012-07-20 | ||
| CN2013078309 | 2013-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092354A1 true AR092354A1 (es) | 2015-04-15 |
Family
ID=49263333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102583A AR092354A1 (es) | 2012-07-20 | 2013-07-22 | Derivados de carbamato/urea |
Country Status (42)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR088256A1 (es) | 2011-10-08 | 2014-05-21 | Novartis Ag | Derivados de carbamato / urea como antagonistas del receptor h3 |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
| EP3391886A1 (en) * | 2017-04-19 | 2018-10-24 | Novartis AG | The use of a h3r inverse agonist for the treatment of shift work disorder |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| AU2019359549A1 (en) | 2018-10-11 | 2021-03-25 | Novartis Ag | The use of a H3R inverse agonist for the treatment of excessive daytime sleepiness associated with parkinson's disease (PD) |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| TW301607B (es) | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| HUP0204496A3 (en) | 2000-01-20 | 2004-07-28 | Eisai Co Ltd | Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same |
| US6849621B2 (en) | 2001-03-13 | 2005-02-01 | Schering Corporation | Piperidine compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1615909B1 (en) | 2003-04-23 | 2008-07-23 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| EP1717230B1 (en) | 2004-02-13 | 2014-08-06 | Msd K.K. | Fused-ring 4-oxopyrimidine derivative |
| SE0401971D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| CN1976926A (zh) | 2004-09-02 | 2007-06-06 | 特瓦制药工业有限公司 | 奥美沙坦酯的制备 |
| CA2575177A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Purification of olmesartan medoxomil |
| EP1909797A4 (en) | 2005-08-02 | 2013-02-27 | Neurogen Corp | DIPIPERAZINYL KETONE AND RELATED ANALOG |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| US20090182140A1 (en) | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| ATE546441T1 (de) * | 2007-12-05 | 2012-03-15 | Astrazeneca Ab | Piperazinderivate und ihre verwendung als modulatoren des leptinrezeptors |
| TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| ES2601007T3 (es) | 2010-01-22 | 2017-02-13 | Taiho Pharmaceutical Co., Ltd. | Compuesto de piperazina que presenta un efecto inhibidor de PGDS |
| TW201217312A (en) * | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| AR088256A1 (es) * | 2011-10-08 | 2014-05-21 | Novartis Ag | Derivados de carbamato / urea como antagonistas del receptor h3 |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
-
2013
- 2013-07-17 US US13/944,354 patent/US9034874B2/en active Active
- 2013-07-18 JP JP2015522234A patent/JP6203841B2/ja active Active
- 2013-07-18 NO NO13770709A patent/NO2875016T3/no unknown
- 2013-07-18 PT PT137707097T patent/PT2875016T/pt unknown
- 2013-07-18 KR KR1020157001045A patent/KR102150739B1/ko active IP Right Grant
- 2013-07-18 SG SG10201700188PA patent/SG10201700188PA/en unknown
- 2013-07-18 ES ES13770709.7T patent/ES2648512T3/es active Active
- 2013-07-18 WO PCT/IB2013/055916 patent/WO2014013469A1/en active Application Filing
- 2013-07-18 HU HUE13770709A patent/HUE035592T2/en unknown
- 2013-07-18 EA EA201590250A patent/EA026091B1/ru not_active IP Right Cessation
- 2013-07-18 MY MYPI2014003308A patent/MY168752A/en unknown
- 2013-07-18 PL PL13770709T patent/PL2875016T3/pl unknown
- 2013-07-18 EP EP13770709.7A patent/EP2875016B1/en active Active
- 2013-07-18 MX MX2015000903A patent/MX362059B/es active IP Right Grant
- 2013-07-18 RS RS20171048A patent/RS56479B1/sr unknown
- 2013-07-18 NZ NZ702346A patent/NZ702346A/en not_active IP Right Cessation
- 2013-07-18 IN IN10449DEN2014 patent/IN2014DN10449A/en unknown
- 2013-07-18 PE PE2015000045A patent/PE20151155A1/es active IP Right Grant
- 2013-07-18 SG SG11201408020RA patent/SG11201408020RA/en unknown
- 2013-07-18 BR BR112015001207-8A patent/BR112015001207B1/pt active IP Right Grant
- 2013-07-18 CN CN201380038422.1A patent/CN104470911B/zh active Active
- 2013-07-18 CU CUP2015000006A patent/CU24248B1/es unknown
- 2013-07-18 AU AU2013291617A patent/AU2013291617B2/en not_active Ceased
- 2013-07-18 AP AP2014008109A patent/AP3710A/en active
- 2013-07-18 SI SI201330787T patent/SI2875016T1/sl unknown
- 2013-07-18 LT LTEP13770709.7T patent/LT2875016T/lt unknown
- 2013-07-18 DK DK13770709.7T patent/DK2875016T3/da active
- 2013-07-18 CA CA2878006A patent/CA2878006C/en active Active
- 2013-07-19 TW TW102125975A patent/TWI597276B/zh active
- 2013-07-19 UY UY0001034921A patent/UY34921A/es unknown
- 2013-07-21 JO JOP/2013/0218A patent/JO3439B1/ar active
- 2013-07-22 AR ARP130102583A patent/AR092354A1/es active IP Right Grant
-
2014
- 2014-11-27 ZA ZA2014/08805A patent/ZA201408805B/en unknown
- 2014-11-28 TN TN2014000497A patent/TN2014000497A1/fr unknown
- 2014-12-05 PH PH12014502743A patent/PH12014502743B1/en unknown
-
2015
- 2015-01-09 CL CL2015000056A patent/CL2015000056A1/es unknown
- 2015-01-11 IL IL236656A patent/IL236656A/en active IP Right Grant
- 2015-01-20 CO CO15009915A patent/CO7170173A2/es unknown
- 2015-01-20 GT GT201500012A patent/GT201500012A/es unknown
- 2015-01-20 CR CR20150019A patent/CR20150019A/es unknown
- 2015-04-14 US US14/685,926 patent/US9273026B2/en active Active
- 2015-05-28 HK HK15105099.2A patent/HK1204609A1/xx not_active IP Right Cessation
-
2016
- 2016-02-22 US US15/049,739 patent/US9624192B2/en active Active
-
2017
- 2017-03-07 US US15/452,430 patent/US20170275264A1/en not_active Abandoned
- 2017-10-25 CY CY20171101112T patent/CY1119492T1/el unknown
- 2017-11-06 HR HRP20171692TT patent/HRP20171692T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092354A1 (es) | Derivados de carbamato/urea | |
| AR124607A2 (es) | Arilquinazolinas | |
| AR115885A1 (es) | Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| AR112687A1 (es) | Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción tricíclica, conjugados de estos y métodos y usos de estos | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR081387A1 (es) | Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos. | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| ECSP11011200A (es) | Derivados de oxadiazale como agonista de los receptores s1p1 | |
| AR104326A1 (es) | Compuestos nucleósidos 5-sustituidos | |
| CR20150661A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas | |
| AR107738A1 (es) | Amidas de ácido n-(5-halógen-1,3,4-oxadiazol-2-il)arilcarboxílico y su uso como herbicidas | |
| AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
| AR090091A1 (es) | Sulfin- y sulfonimidoilbenzamidas de accion herbicida | |
| AR090076A1 (es) | Metodos para producir compuestos sulfilimina | |
| CO6321232A2 (es) | Compuesto de tropano como inhibidores de hsp90 | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| TR201900393T4 (tr) | 1,2-Dihidro-3H-Pirolo[1,2-C]İmidazol-3-On Türevleri Ve Bunların Antibakteriyel Ajanlar Olarak Kullanımı | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| EA201200602A1 (ru) | Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1 | |
| AR088982A1 (es) | Derivados de 2-yodo-imidazol | |
| AR106047A1 (es) | Derivado de biarilo y medicamento que contiene el mismo para el tratamiento de infecciones fúngicas | |
| AR089297A1 (es) | Uso de derivados de diamida antranilicos con sustituyentes heteroaromaticos y heterociclicos en combinacion con un agente de control biologico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |